STEMLINE THERAPEUTICS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | — | $500,000 | $898,199 | $1.0M | — | — |
| Operating income | −$79.2M | −$86.3M | −$68.6M | −$38.9M | −$37.6M | −$29.0M |
| Net income | −$27.4M | −$18.4M | −$67.8M | −$38.3M | −$37.2M | — |
| Total assets | $187.0M | $63.5M | $67.0M | $68.1M | $98.2M | $60.5M |
| Total liabilities | $23.4M | $21.3M | $19.9M | $10.4M | $10.1M | $5.1M |
| Equity | $163.6M | $42.2M | $47.1M | $57.7M | $88.1M | $55.4M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 43.6M | 30.2M | 25.1M | 19.0M | 17.8M | 13.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- —
- Net margin
- —
- Return on equity
- −16.8%
- Return on assets
- −14.7%
- Return on capital (ROCE)
- −48.4%
- Liabilities / assets
- 12.5%
- Debt / equity
- 0.14×
- Book value / share
- $3.76
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- 3.81safe
- Accruals / assets
- 21.5%high accruals
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 2 good- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-06A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 2Active Not Recruitingreadout ~2026-11ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
- Phase 1/2Recruitingreadout ~2026-12Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Phase 1/2Recruitingreadout ~2026-12-27Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- Phase 1Recruitingreadout ~2027-12-02A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
- Phase 2Recruitingreadout ~2028-02-09A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- Phase 3Recruitingreadout ~2029-08A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJun 10, 2020
- Entered a material agreement · Director / officer change · Amended charter or bylaws · Other material eventMay 4, 2020
- Results of operationsMar 13, 2020
- Results of operationsNov 7, 2019
- Entered a material agreementAug 9, 2019
- Results of operationsAug 2, 2019
- Amended charter or bylaws · Shareholder voteJun 28, 2019
- Results of operationsMay 10, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.